-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ming Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock
Ming Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CTO Ming Yan sold 20,000 shares of the firm's stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $11.03, for a total transaction of $220,600.00. Following the completion of the transaction, the chief technology officer now directly owns 7,946,833 shares in the company, valued at approximately $87,653,567.99. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Ming Yan also recently made the following trade(s):
Get Cytek Biosciences alerts:- On Monday, December 19th, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The shares were sold at an average price of $10.38, for a total transaction of $207,600.00.
- On Monday, November 21st, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The shares were sold at an average price of $14.66, for a total transaction of $293,200.00.
Cytek Biosciences Price Performance
Cytek Biosciences stock opened at $11.01 on Friday. Cytek Biosciences, Inc. has a 12-month low of $7.38 and a 12-month high of $16.05. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -1,101.00 and a beta of 0.06. The firm's fifty day moving average price is $11.77 and its 200 day moving average price is $12.97.
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.01). Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. The firm had revenue of $40.48 million for the quarter, compared to analysts' expectations of $43.36 million. Analysts forecast that Cytek Biosciences, Inc. will post 0.04 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in Cytek Biosciences by 20.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 394,034 shares of the company's stock worth $5,800,000 after acquiring an additional 66,045 shares in the last quarter. Advisory Research Inc. acquired a new position in shares of Cytek Biosciences in the 3rd quarter valued at about $614,000. State Street Corp boosted its holdings in shares of Cytek Biosciences by 17.6% in the 3rd quarter. State Street Corp now owns 2,030,253 shares of the company's stock valued at $29,885,000 after buying an additional 304,433 shares during the period. Algert Global LLC boosted its holdings in shares of Cytek Biosciences by 116.5% in the 3rd quarter. Algert Global LLC now owns 46,055 shares of the company's stock valued at $678,000 after buying an additional 24,785 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Cytek Biosciences by 9.2% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 69,822 shares of the company's stock valued at $1,028,000 after buying an additional 5,865 shares during the period. 49.48% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Piper Sandler lifted their price target on shares of Cytek Biosciences from $16.00 to $18.00 in a research note on Monday, November 14th.
About Cytek Biosciences
(Get Rating)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Read More
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
赛特克生物科学公司(纳斯达克代码:CTKB-GET Rating)首席技术官严明在1月19日周四的一次交易中出售了20,000股该公司股票。这些股票以11.03美元的平均价格出售,总成交金额为220,600.00美元。交易完成后,首席技术官现在直接拥有该公司7,946,833股,价值约87,653,567.99美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在美国证券交易委员会网站。
明言最近还进行了以下交易:
到达Cytek生物科学警报:- 12月19日,星期一,明言出售了两万股赛特克生物科学公司的股票。这些股票以10.38美元的平均价格出售,总成交金额为207,600.00美元。
- 11月21日,星期一,明言出售了2万股Cytek Biosciences股票。这些股票以14.66美元的平均价格出售,总成交额为293,200.00美元。
Cytek Bioscions性价比
Cytek Biosciences的股票上周五开盘报11.01美元。Cytek Biosciences,Inc.的12个月低点为7.38美元,12个月高位为16.05美元。该公司市值14.8亿美元,市盈率为-1101.00,贝塔系数为0.06。该公司的50日移动均线价格为11.77美元,200日移动均线价格为12.97美元。
赛特克生物科学公司(纳斯达克代码:CTKB-GET Rating)最近一次发布季度收益报告是在11月9日星期三。该公司公布本季度每股收益(EPS)为0.01美元,低于普遍预期的0.02美元(0.01美元)。Cytek Biosciences的股本回报率为正0.94%,净利润率为负0.47%。该公司当季营收为4,048万美元,高于分析师预期的4,336万美元。分析师预测,Cytek Biosciences,Inc.本财年每股收益将为0.04美元。机构资金流入和流出
几家对冲基金最近增持或减持了该股。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度增持了Cytek Biosciences 20.1%的股份。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有394,034股该公司股票,价值5,800,000美元,此前该公司在上一季度增持了66,045股。咨询研究公司在第三季度收购了Cytek Biosciences股票的新头寸,价值约614,000美元。道富集团在第三季度增持了Cytek Biosciences的股票17.6%。道富银行目前持有该公司2,030,253股股票,价值29,885,000美元,在此期间又购买了304,433股。阿尔盖特全球有限责任公司在第三季度将其持有的赛特克生物科学公司的股票增加了116.5%。阿尔伯特全球有限责任公司现在拥有46,055股该公司的股票,价值678,000美元,在此期间又购买了24,785股。最后,瑞银资产管理美洲公司(UBS Asset Management America Inc.)在第三季度增持了Cytek Biosciences的股票9.2%。瑞银资产管理美洲公司(UBS Asset Management America Inc.)目前持有69,822股该公司股票,价值1,028,000美元,在此期间又购买了5,865股。49.48%的股票由机构投资者和对冲基金持有。
华尔街分析师也加入进来
另外,派珀·桑德勒在11月14日星期一的一份研究报告中将Cytek Biosciences的目标股价从16.00美元上调至18.00美元。
关于赛特克生物科学公司
(获取评级)
Cytek Biosciences,Inc.是一家细胞分析解决方案公司,提供细胞分析工具,促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统,这是一种光谱流动细胞仪,通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析;以及极光细胞分选系统,它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
阅读更多内容
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧